ALS TDI Completes Gene Expression Profile Of Lou Gehrig’s Disease In Mice
The ALS Therapy Development Institute (ALS TDI) announced that it has completed the first phase of a comprehensive gene expression database for ALS with the profiling of the SOD1 mouse model of amyotrophic lateral sclerosis — ALS, or Lou Gehrig’s disease. The second phase, profiling of human samples, is scheduled for completion by February of 2008.
